Lupin and AbbVie in pacht to develop and commercialize novel oncology drugs

摘要

Lupin Ltd.and global biopharmaceuti-cal company AbbVie Inc.,have announced that AbbVie has licensed Lupin's MALT1(Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1)inhibitor program.Through this partnership,AbbVie gains exclusive global rights to develop and commercialize Lupin's MALT1 inhibitors.MALT-1 is a protein involved in T-cell and B-cell lymphocyte activation and AbbVie intends to pursue development across a range of hematological cancers,many with limited current treatment options.